VIJAY YERROJU

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial
  Vaccines 2026 DOI: 10.3390/vaccines14060464
  +Save
• Immunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
  The Lancet Regional Health - Southeast Asia 2026 DOI: 10.1016/j.lansea.2026.100746
  +Save
• Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply
  The Lancet Regional Health - Southeast Asia 2025 DOI: 10.1016/j.lansea.2025.100678
  +Save
• Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial
  The Lancet Regional Health - Southeast Asia 2025 DOI: 10.1016/j.lansea.2025.100642
  +Save
• A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.
  Vaccine: X 2025 DOI: 10.1016/j.jvacx.2025.100669
  +Save
• Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEVⓇ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study
  IJID Regions 2025 DOI: 10.1016/j.ijregi.2025.100611
  +Save
• Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries
  Vaccine 2025 DOI: 10.1016/j.vaccine.2025.126727
  +Save
• Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
  Human Vaccines & Immunotherapeutics 2023 DOI: 10.1080/21645515.2023.2203632
  +Save
• A multi-center, randomized, controlled, phase-2/3 study to evaluate the safety and immunogenicity of inactivated Japanese encephalitis vaccine in healthy ≥1 to <3 years old Indian children
  International Journal of Clinical Trials 2023 DOI: 10.18203/2349-3259.ijct20231104
  +Save
• Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study
  2023 DOI: 10.1101/2022.12.29.22284049
  +Save